![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca’s Imfinzi Approved in Europe for Small-Cell Lung Cancer
AstraZeneca’s Imfinzi Approved in Europe for Small-Cell Lung Cancer
The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as a first-line treatment for adults with extensive-stage, small-cell lung cancer (ES-SCLC) in combination with chemotherapy.
The approval is for use along with etoposide plus either carboplatin or cisplatin. It was based on results of a phase 3 clinical trial, in which Imfinzi with chemotherapy improved overall survival for ES-SCLC patients.
Imfinzi is also approved in the U.S., Japan and several other countries for the same indication.
Upcoming Events
-
21Oct